2018 Fiscal Year Final Research Report
Development of non-invasive retina-targeted siRNA delivery system for overcoming a blood-retina barrier
| Project/Area Number |
16K01397
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Fukuhara Takeshi
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Keywords | siRNA delivery / リポソーム / モノクローナル抗体 / 網膜 / 点眼 |
|---|
| Outline of Final Research Achievements |
The objective is to prepare the non-invasive retina-targeted nanocarriers for siRNA delivery to suppress the production of vascular endothelium growth factor which cause retina disease leading to late-blindness. The monoclonal antibody (mAb) which has specific internalizing ability to retinal pigment epithelium (RPE) was produced and followed by modification to liposomes which encapsulate complexes of siRNA and multifunctional peptide. The mAb-modified liposome shows small particle size which is permeable to retina through choroid. In addition, the mAb-liposomes was extremely accumulated in the isolated retinal membrane by eye drop to rat.
|
| Free Research Field |
製剤設計学、薬物送達学
|
| Academic Significance and Societal Importance of the Research Achievements |
眼には血液網膜関門等の高度なバリア機能が在るため、網膜への薬物送達は容易ではなく、中途失明や視力低下を起こす網膜疾患に対しては硝子体内への直接注射等の侵襲的な薬物治療がなされる。本研究において、標的とする網膜に指向性を示すモノクローナル抗体を組み込んだ微小キャリアを設計し、通常困難とされる点眼投与によって病因タンパク質の産生を細胞レベルで阻害する核酸の送達が可能であることを明らかとした。本研究での知見は患者の身体的・精神的負担を軽減する薬物治療への貢献が期待される。
|
